1. Home
  2. SPRO vs GDHG Comparison

SPRO vs GDHG Comparison

Compare SPRO & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.14

Market Cap

71.0M

Sector

Health Care

ML Signal

N/A

Logo Golden Heaven Group Holdings Ltd.

GDHG

Golden Heaven Group Holdings Ltd.

N/A

Current Price

$1.11

Market Cap

73.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
GDHG
Founded
2013
2008
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Services-Misc. Amusement & Recreation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
71.0M
73.8M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
SPRO
GDHG
Price
$1.14
$1.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
355.5K
125.5K
Earning Date
05-13-2026
07-11-2025
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$1.06
52 Week High
$3.08
$8.00

Technical Indicators

Market Signals
Indicator
SPRO
GDHG
Relative Strength Index (RSI) 32.01 37.50
Support Level $1.13 $1.06
Resistance Level $1.29 $1.98
Average True Range (ATR) 0.04 0.11
MACD 0.01 -0.01
Stochastic Oscillator 15.53 11.43

Price Performance

Historical Comparison
SPRO
GDHG

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.

Share on Social Networks: